Health breakthroughs and money matters, in plain words

Home » How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation

How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation

By

–

How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation

PARSIPPANY, November 16, 2026 — The FDA has approved Teva’s Igalmi (dexmedetomidine) sublingual film for at-home use to treat acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. This approval marks a significant shift in the treatment of agitation associated with these conditions, as it is the first FDA-approved treatment that can be used at home.

What Is Igalmi And How Does It Differ From Traditional Treatments

Igalmi is a 120 mcg, central alpha-2 adrenergic receptor agonist that works by stopping the brain from releasing the stress hormone norepinephrine, which in turn lowers heart rate and blood pressure. This mechanism of action is different from traditional antipsychotic treatments, which often target dopamine receptors in the brain. According to Teva, Igalmi is available as a sublingual film that can be placed under the tongue or between the lower lip and gum, making it a convenient option for at-home use.

History And Expansion Of Igalmi

Igalmi was originally approved in April 2022 as an orally dissolving film to treat agitation under medical supervision. The recent FDA approval expands its use to at-home settings without healthcare-provider supervision, filling a gap in treatment options for patients with schizophrenia or bipolar disorder. Teva acquired Igalmi through the purchase of assets from BioXcel Therapeutics, and the company plans to announce commercialization plans for Igalmi’s at-home use at a later date.

How Igalmi Works And Its Benefits

The Phase 3 SERENITY At-Home Safety and Tolerability Trial evaluated 1,160 agitation episodes in 102 patients and found that Igalmi met its primary endpoint of safety and tolerability in the at-home setting. The most commonly reported adverse events were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. According to Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva, “For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them. With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it.”

The Key Numbers And What They Mean

Agitation affects an estimated 25% to 40% of patients across schizophrenia, schizoaffective disorder, and bipolar disorders, and up to 21% of acute agitation episodes lead to emergency care utilization or hospitalization. The approval of Igalmi for at-home use provides patients and caregivers with a new option to manage these episodes, potentially reducing the need for emergency care and hospitalization. As Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva, noted, “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”

What This Approval Means For Patients And Caregivers

The FDA approval of Igalmi for at-home use marks a significant step forward in the treatment of agitation associated with schizophrenia and bipolar disorder. Patients and caregivers now have access to a convenient and effective treatment option that can be used in the comfort of their own homes. As with any medication, it is essential for patients to talk to their doctor before using Igalmi, especially if they have a history of low blood pressure or slow heart rate. Patients should follow the recommended dosage and administration instructions to minimize the risk of side effects. The encouraging part is that Igalmi has been shown to be safe and effective in clinical trials, offering hope for patients and caregivers who have been struggling to manage agitation episodes. Patients should consult their doctor to determine if Igalmi is right for them.

Sources

Photo: Brett Jordan / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News